Leutz Buon

704 total citations
28 papers, 368 citations indexed

About

Leutz Buon is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Leutz Buon has authored 28 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 20 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Leutz Buon's work include Multiple Myeloma Research and Treatments (18 papers), DNA Repair Mechanisms (6 papers) and Cancer Mechanisms and Therapy (5 papers). Leutz Buon is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), DNA Repair Mechanisms (6 papers) and Cancer Mechanisms and Therapy (5 papers). Leutz Buon collaborates with scholars based in United States, France and India. Leutz Buon's co-authors include Nikhil C. Munshi, Masood A. Shammas, Kenneth C. Anderson, Jialan Shi, Jagannath Pal, Subodh Kumar, Srikanth Talluri, Douglas W. McMillin, Paul G. Richardson and Constantine S. Mitsiades and has published in prestigious journals such as Blood, Gastroenterology and Cancer Research.

In The Last Decade

Leutz Buon

27 papers receiving 367 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leutz Buon United States 10 241 133 113 56 44 28 368
Lenka Bešše Switzerland 12 248 1.0× 121 0.9× 186 1.6× 56 1.0× 66 1.5× 39 399
Vishnupriya Satti India 13 243 1.0× 70 0.5× 69 0.6× 39 0.7× 106 2.4× 30 397
Valerie Morris United States 8 178 0.7× 108 0.8× 38 0.3× 49 0.9× 70 1.6× 16 311
Naïs Prade France 7 197 0.8× 95 0.7× 176 1.6× 90 1.6× 38 0.9× 8 395
Rachael A. Safyan United States 8 111 0.5× 151 1.1× 53 0.5× 32 0.6× 72 1.6× 28 257
Kadriye Nehir Cosgun United States 6 185 0.8× 77 0.6× 157 1.4× 172 3.1× 62 1.4× 19 413
Renate Schwab Australia 9 193 0.8× 79 0.6× 77 0.7× 28 0.5× 45 1.0× 16 358
Paola Rivera-Muñoz France 9 322 1.3× 129 1.0× 70 0.6× 115 2.1× 49 1.1× 10 440
Carl Sandén Sweden 11 198 0.8× 91 0.7× 187 1.7× 137 2.4× 54 1.2× 18 426
Zhuogang Liu China 9 136 0.6× 78 0.6× 107 0.9× 36 0.6× 40 0.9× 38 268

Countries citing papers authored by Leutz Buon

Since Specialization
Citations

This map shows the geographic impact of Leutz Buon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leutz Buon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leutz Buon more than expected).

Fields of papers citing papers by Leutz Buon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leutz Buon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leutz Buon. The network helps show where Leutz Buon may publish in the future.

Co-authorship network of co-authors of Leutz Buon

This figure shows the co-authorship network connecting the top 25 collaborators of Leutz Buon. A scholar is included among the top collaborators of Leutz Buon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leutz Buon. Leutz Buon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ray, Arghya, Leutz Buon, Ting Du, et al.. (2025). Targeting Siglec–sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma. Blood Advances. 9(19). 5085–5090.
2.
Ray, Arghya, Yan Song, Ting Du, et al.. (2024). Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples. Blood. 144(Supplement 1). 1947–1947. 1 indexed citations
3.
Kumar, Subodh, Srikanth Talluri, Leutz Buon, et al.. (2023). ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma. Blood. 143(11). 996–1005. 3 indexed citations
4.
Kumar, Subodh, Srikanth Talluri, Leutz Buon, et al.. (2023). Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma. Gastroenterology. 165(2). 357–373. 7 indexed citations
5.
Ray, Arghya, Yan Song, Ting Du, et al.. (2022). Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma. Blood Cancer Journal. 12(4). 50–50. 11 indexed citations
6.
Talluri, Srikanth, Shidai Mu, Subodh Kumar, et al.. (2022). RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. Cancers. 14(22). 5697–5697. 15 indexed citations
7.
Kumar, Subodh, Leutz Buon, Srikanth Talluri, et al.. (2021). Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. Communications Biology. 4(1). 617–617. 7 indexed citations
8.
Bhatt, Shruti, Jeremy Ryan, Leutz Buon, et al.. (2021). Abstract NG14: Reduction in mitochondrial priming drives resistance to targeted therapy in acute myeloid leukemia. Cancer Research. 81(13_Supplement). NG14–NG14. 1 indexed citations
9.
Talluri, Srikanth, Mehmet Samur, Leutz Buon, et al.. (2021). Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer Journal. 11(10). 166–166. 25 indexed citations
10.
Alagpulinsa, David A., Subodh Kumar, Srikanth Talluri, et al.. (2019). Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Advances. 3(23). 3968–3972. 12 indexed citations
11.
Ray, Arghya, Leutz Buon, Yan Song, Dharminder Chauhan, & Kenneth C. Anderson. (2019). Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells. Blood. 134(Supplement_1). 510–510. 3 indexed citations
12.
Talluri, Srikanth, Mehmet Samur, Leutz Buon, et al.. (2017). Apobec Family of Proteins Mediate Genomic Changes in Multiple Myeloma By Inducing DNA Damage and C>T Mutations. Blood. 130. 4334–4334. 1 indexed citations
13.
Pal, Jagannath, Subodh Kumar, Jialan Shi, et al.. (2017). Impact of RAD51C-mediated Homologous Recombination onGenomic Integrity in Barrett’s Adenocarcinoma Cells. Journal of Gastroenterology and Hepatology Research. 6(1). 2286–2295. 9 indexed citations
14.
Shammas, Masood A., Leutz Buon, Subodh Kumar, et al.. (2016). Flap Structure-Specific Endonuclease 1 (FEN1) May be a Key Mediator of Genome Instability in Myeloma: A Cellular Vulnerability with Potential Therapeutic Significance. Blood. 128(22). 4440–4440. 1 indexed citations
15.
Lu, Rongzhu, Jagannath Pal, Leutz Buon, et al.. (2013). Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene. 33(12). 1495–1505. 37 indexed citations
16.
McMillin, Douglas W., Hannah M. Jacobs, Jake Delmore, et al.. (2012). Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. Molecular Cancer Therapeutics. 11(4). 942–951. 46 indexed citations
17.
McMillin, Douglas W., Jake Delmore, Joseph Negri, et al.. (2011). Molecular and cellular effects of multi‐targeted cyclin‐dependent kinase inhibition in myeloma: biological and clinical implications. British Journal of Haematology. 152(4). 420–432. 24 indexed citations
18.
Pal, Jagannath, Robert C. Bertheau, Leutz Buon, et al.. (2011). Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene. 30(33). 3585–3598. 39 indexed citations
19.
Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations
20.
Munshi, Nikhil C., Hervé Avet‐Loiseau, Phil Stephens, et al.. (2009). Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. Blood. 114(22). 2846–2846. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lenka Bešše Breakdown of academic impact, for papers by Vishnupriya Satti Breakdown of academic impact, for papers by Valerie Morris Breakdown of academic impact, for papers by Naïs Prade Breakdown of academic impact, for papers by Rachael A. Safyan Breakdown of academic impact, for papers by Kadriye Nehir Cosgun Breakdown of academic impact, for papers by Renate Schwab Breakdown of academic impact, for papers by Paola Rivera-Muñoz Breakdown of academic impact, for papers by Carl Sandén Breakdown of academic impact, for papers by Zhuogang Liu
Rankless by CCL
2026